Damages return to haunt Boston in Johnson & Johnson patent case
This article was originally published in Clinica
A Delaware Jury has found that Boston Scientific's NIR stent - which the company no longer sells - infringes Johnson & Johnson's Palmaz patent. No monetary damages have yet been set. Further post-verdict motions and hearings and an appeal by Boston Scientific are also expected. The verdict followed a retrial of earlier litigation in which J&J was awarded damages of $324m in 2000.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”